
XTANDI Delivers Long-Term Survival in Metastatic Hormone-Sensitive Prostate Cancer
Astellas and Pfizer Showcase Five-Year Survival Benefits of XTANDI in Metastatic Hormone-Sensitive Prostate Cancer at ASCO 2025 In a pivotal milestone for prostate cancer treatment, Astellas Pharma Inc. and Pfizer…











